JMP Securities raised the firm’s price target on Prothena to $85 from $81 and keeps an Outperform rating on the shares following the quarterly results. Headlined by progress on PRX012, Prothena’s broad pipeline continues to advance, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRTA: